Fundraising Fox
Slate Bio
Charlottesville, US · Founded 2020 · Delaware corporation · 4 employees on LinkedIn · 2 known investors
Find your way into Slate Bio
Sign up to find every way you can get introduced to Slate Bio
- Your email: who you already know at Slate Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Slate Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
Founders & leadership
RC
Robert CreedenNamed on SEC filing
KW
Kurt WoerpelNamed on SEC filing
AJ
Andrew J KrouseNamed on SEC filing
Board
KS
Investors · 2
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 2 rounds · 2020–2022
▶$2.8MraisedMay 2023 · 9 investors · Other Health CareRule 506(b)
▶$2.8MraisedMay 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KrouseExecutive Officer, Director
- Kurt WoerpelExecutive Officer
- Robert CreedenDirector
- Kyparissia SirinakisDirector
- Brian GallagherDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2MraisedJun 2021 · 10 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CreedenDirector
- Kurt WoerpelExecutive Officer
- Kyparissia SirinakisDirector
- Andrew J KrouseExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Slate MedicinesSlate Medicines is a clinical-stage biotechnology company. The page profiles an executive but provides limited detail on the company's specific therapeutic focus.
Milestone PharmaceuticalsMilestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Forbion CapitalA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
Companies working in the same space as Slate Bio.
Frequently asked questions
- What does Slate Bio do?
- Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
- Who are Slate Bio's investors?
- Slate Bio's investors include Epidarex Capital, VTC Ventures.
- How much funding has Slate Bio raised?
- Slate Bio has disclosed $4.8M raised across 2 rounds.
- Where is Slate Bio headquartered?
- Slate Bio is headquartered in Charlottesville, US.